New
HealthMore in Health→
Next-Generation ADCs Face a Clinical Trial Bottleneck
Key Takeaways
- A Nature Medicine perspective says ADC innovation is outpacing clinical trial capacity.
- The authors argue single design tweaks are unlikely to deliver major gains on their own.
- Better molecular tools and diversified ADC libraries could support more personalized cancer treatment.
DE
DT Editorial Team··via nature.com
